Clinical Trials Logo

MDS-EB clinical trials

View clinical trials related to MDS-EB.

Filter by:
  • None
  • Page 1

NCT ID: NCT05933070 Terminated - Cancer Clinical Trials

A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

LAUREL
Start date: June 15, 2020
Phase: Phase 1
Study type: Interventional

INMB-INB16-002 is a Phase I open-label, dose escalation study of INKmune therapy in subjects with myelodysplastic syndrome (MDS) with excess blasts without Auer rods (EB-1 or 2, or CMML 1 or 2) or subjects with acute myeloid leukaemia (AML) in complete remission.

NCT ID: NCT04599426 Not yet recruiting - MDS-EB Clinical Trials

Allogenic NK Cell Transfusion Azacitidine MDS-EB

Start date: December 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for refractory MDS-EB.

NCT ID: NCT04216355 Recruiting - MDS-EB Clinical Trials

Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

Start date: January 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .